Actress Alyson Hannigan Stages An “Allergy Intervention” For The Millions Of Americans Living With Seasonal Nasal Allergies

WASHINGTON, April 20, 2016 – The Asthma and Allergy Foundation of America (AAFA) and Teva Respiratory today announced the launch of Allergy Intervention: Because Allergies Aren’t Funny, an initiative aimed at raising awareness of the seriousness of nasal allergies and encouraging patients to be proactive in managing their symptoms. The campaign features comedic film and television actress and mother Alyson Hannigan, who is speaking publicly for the first time about her personal experience living with seasonal allergies, as well as her children’s. For more information about the campaign, including how to enter the Allergy Intervention sweepstakes for a chance to win an AAFA Certified asthma & allergy friendly™ Dyson vacuum, visit
“I’ve lived with seasonal allergies for as long as I can remember. Anytime the weather changes, my nasal allergy symptoms flare up, especially in the spring,” said Alyson Hannigan, campaign spokesperson. “As a mom of two active kids who also live with seasonal allergies and love to be outside, preparedness is key in helping us keep our symptoms under control. Every year, I work closely with our doctor to ensure our allergy treatment plans are in place and up-to-date before our symptoms begin. Because, let’s face it, the bothersome symptoms of nasal allergies just aren’t funny!”
Allergy Intervention



Allergy Intervention

Allergic rhinitis, or nasal allergies, affects approximately 50 million people living in the United States. Symptoms include sneezing, stuffy or runny nose, itching of the nose, and are usually caused by allergic sensitivity to pollens from trees, grass or weeds, or to airborne mold spores.i
“Allergies affect millions of people across the country and while they may seem like a common occurrence, symptoms of nasal allergies are no laughing matter,” said Wendy Rees, Vice President of Marketing and Communications at AAFA. “Our hope is that by partnering with Alyson Hannigan and Teva Respiratory, we will raise awareness about the seriousness of seasonal allergies and encourage patients to proactively work with their personal clinicians to find the best possible management plan for them.”
For more information, visit
About Allergic Rhinitis

Allergic rhinitis (AR) is a chronic inflammatory disease characterized by symptoms such as sneezing, nasal itch, runny nose and nasal congestion. For many AR patients, nasal congestion or a stuffy nose may be the most frequent and bothersome symptom.
According to the American Academy of Allergy, Asthma and Immunology (AAAAI), the prevalence of AR in the U.S. has increased during the past three decades; it is recently estimated at 20 percent in the general adult and adolescent populations. Of those Americans affected with AR, approximately 20 percent have seasonal allergy rhinitis (SAR), 40 percent have perennial allergic rhinitis (PAR) and 40 percent have a combination of the two (i.e., PAR with seasonal exacerbation) depending on the allergen sensitivity. Because of its prevalence and health effect, AR is associated with considerable direct and indirect costs.
About AAFA 

Founded in 1953 and celebrating over 60 years of service, the Asthma and Allergy Foundation of America (AAFA) is the oldest and largest nonprofit patient organization dedicated to improving the quality of life for people with asthma, allergies and related conditions through education, advocacy and research. AAFA provides practical information, community-based services, support and referrals through a national network of chapters and educational support groups. Through its Kids With Food Allergies division, AAFA offers the oldest, most extensive online support community for families raising children with food allergies at In addition, AAFA sponsors and advocates for research to advance the basic science relevant to treatment and cure. It also champions translational research so that the science that we have is applied more consistently and reliably. For more information, visit

Comments are closed.